AnteoTech Limited

ADO

AU000000ADO8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:40:22 23/05/2024 am IST			5-day change	1st Jan Change
0.025 ^AUD	+4.17%		+13.64%	-30.56%

14/05	AnteoTech Completes AU$1.4 Million Share Purchase Plan	MT
02/05	AnteoTech Extends Closing Date of Share Purchase Plan	MT

AnteoTech Limited Announces Resignation of Mat Sanderson as Non-Executive Director

April 22, 2021 at 12:48 pm IST

The Board of AnteoTech Ltd. announced that Non-Executive Director, Mat Sanderson has resigned as a Director, effective 22 April 2021.

Latest news about AnteoTech Limited

AnteoTech Completes AU$1.4 Million Share Purchase Plan	14/05	MT
AnteoTech Extends Closing Date of Share Purchase Plan	02/05	MT
Anteotech Seeks to Raise AU$6 Million From Share Placement; Shares Fall 26%	08/04	MT
AnteoTech Receives AU$1.39 Million from Queensland Critical Minerals and Battery Technology Fund; Shares Down 3%	27/03	MT
AnteoTech Settles Patent Claims for AU$300,000	04/03	MT
AnteoTech Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02	CI
Anteotech Completes Construction of Anteo X Production Facility in Brisbane; Shares Climb 6%	15/02	MT
AnteoTech Produces Anode Material Containing Proprietary Technology	07/12	MT
AnteoTech Receives AU$3.8 Million R&D Tax Rebate; Shares Rise 3%	12/23/12	MT
AnteoTech Limited(ASX:ADO) dropped from S&P Global BMI Index	18/23/18	CI
AnteoTech Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
AnteoTech Limited Announces Appointment of Mr. Andrew Cook as Company Secretary, Effective from 28 August 2023	22/23/22	CI
Anteotech Limited Announces Appointment of Mr. Andrew Cook as Chief Financial Officer	22/23/22	CI
AnteoTech Halts Trade	24/23/24	MT
AnteoTech Limited Announces Retirement of Christopher Parker from the Board of Directors	27/23/27	CI
Anteotech to Undergo Major Rebranding; Shares Jump 10%	23/23/23	MT
Anteotech Limited Announces Changes to Leadership Team	01/23/01	CI
Anteotech Limited Announces Changes to Leadership Team	01/23/01	CI
AnteoTech Limited(ASX:ADO) dropped from S&P/ASX Emerging Companies Index	20/23/20	CI
AnteoTech Limited(ASX:ADO) dropped from S&P/ASX All Ordinaries Index	20/23/20	CI
Anteotech, Wyon to Collaborate on Silicon Anodes for Micro-Batteries	02/23/02	MT
Anteotech, Trinseo Europe Sign Deal to Develop New Product	22/23/22	MT
AnteoTech Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/23/22	CI
AnteoTech Appoints Chief Marketing Officer	15/23/15	MT
AnteoTech Limited Appoints Tsui Min Lian as Chief Marketing Officer, Effective 15 March 2023	15/23/15	CI

AnteoTech Limited is an Australia-based company engaged in providing solutions for the clean energy and life sciences markets using applied materials technology. The principal activities of the Company consist of development and commercialization of nanotechnologies with surface management applications. The Companyâs lead product, Anteo X, provides significant improvement in anode performance and the Company partners with global suppliers in lithium-ion battery manufacturing. Its clean energy technology (CET) technologies improve the energy densities, cycle life and cost- effectiveness of lithium-ion batteries. The Company has two programs underway: Anteo X, its binder additive and the High Silicon Anode technology. The Life Sciences division services the point-of-care and in vitro diagnostics markets from global diagnostics companies to technology developers. Its AnteoBind provides advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

Sector

Biotechnology & Medical Research

Calendar

28/05/2024 - Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ANTEOTECH LIMITED	-30.56%	38.38M
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+43.96%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B

Other Biotechnology & Medical Research